Brandon Capital Partners
Alex Delbridge PhD is a Principal on the Investment Team at Brandon Capital, effective August 2025. Delbridge has extensive experience in the biotechnology and pharmaceutical sectors, having served as a Board Observer for companies like BridgeBio Oncology Therapeutics, NRG Therapeutics, Scorpion Therapeutics, and Photys Therapeutics, with notable achievements including involvement in Scorpion Therapeutics' acquisition by Eli Lilly for up to $2.5 billion. Prior roles include Senior Investment Associate at Omega Funds and Consultant at Putnam Associates, where Delbridge provided commercial strategy guidance to leading pharmaceutical clients. Academic qualifications include a Ph.D. in Oncology and Cancer Biology from the University of Melbourne, along with credentials in business readiness and leadership from Harvard Business School Online and the University of Melbourne.
This person is not in any teams
This person is not in any offices